Kforce Inc. (KFRC) Reaches $34.50 52-Week High; Genocea Biosciences, Inc. (GNCA) Had 8 Analysts Last Week

June 12, 2018 - By Henry Gaston

Kforce Inc. (NASDAQ:KFRC) Logo

The stock of Kforce Inc. (NASDAQ:KFRC) hit a new 52-week high and has $36.92 target or 7.00% above today’s $34.50 share price. The 8 months bullish chart indicates low risk for the $851.05 million company. The 1-year high was reported on Jun, 12 by Barchart.com. If the $36.92 price target is reached, the company will be worth $59.57 million more. The stock decreased 0.58% or $0.2 during the last trading session, reaching $34.5. About 8,915 shares traded. Kforce Inc. (NASDAQ:KFRC) has risen 75.81% since June 12, 2017 and is uptrending. It has outperformed by 63.24% the S&P500. Some Historical KFRC News: ; 01/05/2018 – Kforce Non-Deal Roadshow Set By Northcoast Research for May. 8; 01/05/2018 – Kforce 1Q Rev $346.3M; 01/05/2018 – KFORCE 1Q EPS 37C, EST. 36C; 19/04/2018 – DJ Kforce Inc, Inst Holders, 1Q 2018 (KFRC); 10/05/2018 – Kforce Presenting at Conference Jun 6; 01/05/2018 – KFORCE 1Q REV. $346.3M, EST. $345.0M; 01/05/2018 – KFORCE SEES 2Q EPS $355M TO $360M, EST. 61C; 15/05/2018 – Hancock Holding Buys New 1.1% Position in Kforce; 20/03/2018 Kforce at Non-Deal Roadshow Hosted By Northcoast Research Today; 11/05/2018 – Broadview Advisors LLC Exits Position in Kforce

Among 9 analysts covering Genocea Biosciences (NASDAQ:GNCA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Genocea Biosciences had 20 analyst reports since August 6, 2015 according to SRatingsIntel. On Thursday, December 17 the stock rating was initiated by UBS with “Buy”. As per Monday, October 19, the company rating was maintained by FBR Capital. The firm has “Buy” rating by Cowen & Co given on Monday, July 24. The rating was initiated by Cantor Fitzgerald on Monday, March 5 with “Buy”. The firm has “Buy” rating by Needham given on Tuesday, February 6. As per Friday, November 3, the company rating was maintained by Needham. The company was maintained on Thursday, April 19 by H.C. Wainwright. As per Thursday, August 6, the company rating was maintained by Piper Jaffray. Cowen & Co maintained Genocea Biosciences, Inc. (NASDAQ:GNCA) on Wednesday, August 9 with “Buy” rating. The stock has “Buy” rating by Needham on Tuesday, October 20. See Genocea Biosciences, Inc. (NASDAQ:GNCA) latest ratings:

30/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain
19/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain
08/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5 Initiates Coverage On
05/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $5.0 Initiate
12/02/2018 Broker: Robert W. Baird Rating: Outperform New Target: $3 Initiates Coverage On
06/02/2018 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade

The stock decreased 0.95% or $0.0089 during the last trading session, reaching $0.9306. About 17,787 shares traded. Genocea Biosciences, Inc. (NASDAQ:GNCA) has declined 84.29% since June 12, 2017 and is downtrending. It has underperformed by 96.86% the S&P500. Some Historical GNCA News: ; 10/05/2018 – GENOCEA BIOSCIENCES INC – QTRLY SHR LOSS $0.21; 18/04/2018 – Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods; 26/03/2018 – Genocea Biosciences Presenting at Conference Tomorrow; 22/04/2018 – DJ Genocea Biosciences Inc, Inst Holders, 1Q 2018 (GNCA); 10/05/2018 – Genocea Biosciences 1Q Loss/Shr 21c; 30/04/2018 – Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009; 16/05/2018 – Pure Play Health Care FUnds Buy Genocea, Exit Axovant: 13F; 09/03/2018 GENOCEA BIOSCIENCES – ON MARCH 6, JONATHAN POOLE DELIVERED RESIGNATION AS CFO EFFECTIVE MARCH 23, 2018; 10/05/2018 – Genocea Biosciences 1Q Loss $15.3M; 09/04/2018 – Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines

Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company has market cap of $80.58 million. The firm uses AnTigen Lead Acquisition System , its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. It currently has negative earnings. The Company’s lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections.

Another recent and important Genocea Biosciences, Inc. (NASDAQ:GNCA) news was published by Globenewswire.com which published an article titled: “Genocea to Present at Jefferies 2018 Global Healthcare Conference” on June 01, 2018.

More recent Kforce Inc. (NASDAQ:KFRC) news were published by: Nasdaq.com which released: “Report: Exploring Fundamental Drivers Behind Titan Machinery, Kforce, Liberty Media, Daktronics, SPX, and Tallgrass …” on May 29, 2018. Also Investorplace.com published the news titled: “Jobs Report Paints a Pretty Picture for These Top 5 Stocks” on June 04, 2018. Benzinga.com‘s news article titled: “40 Biggest Movers From Friday” with publication date: June 04, 2018 was also an interesting one.

Investors sentiment increased to 1.31 in 2018 Q1. Its up 0.11, from 1.2 in 2017Q4. It increased, as 8 investors sold Kforce Inc. shares while 47 reduced holdings. 29 funds opened positions while 43 raised stakes. 19.44 million shares or 6.59% less from 20.81 million shares in 2017Q4 were reported. Us Bank & Trust De invested in 7,996 shares or 0% of the stock. Howe & Rusling stated it has 255 shares or 0% of all its holdings. Arrowstreet Partnership holds 0% or 38,414 shares in its portfolio. Swiss Natl Bank has 41,100 shares for 0% of their portfolio. 335,533 were reported by Lsv Asset. Prudential has 0.01% invested in Kforce Inc. (NASDAQ:KFRC). Citadel Advisors Limited Liability Com invested in 105,136 shares or 0% of the stock. Voya Investment Management Limited Liability Company stated it has 0% in Kforce Inc. (NASDAQ:KFRC). 6,289 are held by Bessemer Gru. 134,150 are owned by Paradigm Capital Mngmt Inc Ny. Federated Incorporated Pa holds 0% or 25,667 shares. State Board Of Administration Of Florida Retirement Systems stated it has 30,054 shares. Art Ltd Liability holds 0.03% or 23,217 shares in its portfolio. Cambridge Investment Rech Advisors holds 0.01% of its portfolio in Kforce Inc. (NASDAQ:KFRC) for 29,598 shares. Verition Fund Ltd Liability Corp invested in 7,512 shares or 0.02% of the stock.

Since December 14, 2017, it had 0 insider purchases, and 25 insider sales for $7.65 million activity. 21,380 shares were sold by LIBERATORE JOSEPH J, worth $580,467 on Tuesday, January 9. DUNKEL DAVID L also sold $10,282 worth of Kforce Inc. (NASDAQ:KFRC) on Friday, December 15. Mitchell Kye L. had sold 15,907 shares worth $392,108 on Monday, February 12. ROSEN ELAINE had sold 5,000 shares worth $135,900 on Wednesday, February 14. $204,569 worth of Kforce Inc. (NASDAQ:KFRC) was sold by BLACKMAN MICHAEL R. 1,229 Kforce Inc. (NASDAQ:KFRC) shares with value of $33,244 were sold by STRUZZIERO RALPH. 2,500 shares valued at $71,625 were sold by ALLRED JOHN on Friday, March 9.

Kforce Inc. provides professional and technical specialty staffing services and solutions in the United States and internationally. The company has market cap of $851.05 million. It operates through three divisions: Technology , Finance and Accounting (FA), and Government Solutions (GS). It has a 26.54 P/E ratio. The Tech segment provides temporary staffing and permanent placement services to its clients primarily in the areas of information technology, such as systems/applications architecture and development, project management, enterprise data management, business intelligence, e-commerce, technology infrastructure, network architecture, and security.

Among 6 analysts covering Kforce.com (NASDAQ:KFRC), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Kforce.com had 13 analyst reports since November 4, 2015 according to SRatingsIntel. The company was downgraded on Friday, February 24 by Credit Suisse. The rating was upgraded by Avondale to “Mkt Outperform” on Wednesday, February 8. The stock of Kforce Inc. (NASDAQ:KFRC) has “Hold” rating given on Wednesday, October 11 by SunTrust. The rating was maintained by SunTrust on Wednesday, January 31 with “Hold”. The stock of Kforce Inc. (NASDAQ:KFRC) earned “Outperform” rating by Robert W. Baird on Wednesday, February 7. As per Tuesday, February 6, the company rating was maintained by Northcoast. The company was downgraded on Monday, December 19 by Avondale. Deutsche Bank maintained Kforce Inc. (NASDAQ:KFRC) on Wednesday, August 2 with “Hold” rating. The firm has “Hold” rating given on Thursday, August 18 by Deutsche Bank. Robert W. Baird maintained it with “Buy” rating and $20.0 target in Monday, September 11 report.

Analysts await Kforce Inc. (NASDAQ:KFRC) to report earnings on August, 7. They expect $0.63 earnings per share, up 43.18% or $0.19 from last year’s $0.44 per share. KFRC’s profit will be $15.54M for 13.69 P/E if the $0.63 EPS becomes a reality. After $0.37 actual earnings per share reported by Kforce Inc. for the previous quarter, Wall Street now forecasts 70.27% EPS growth.

Kforce Inc. (NASDAQ:KFRC) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>